Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of a pd-1 antagonist and eribulin for treating urothelial cancer

A technology for urothelial carcinoma and PD-1, applied in drug combinations, antibodies, anti-tumor drugs, etc., can solve problems such as impaired immune response

Pending Publication Date: 2019-07-30
MERCK & CO INC +1
View PDF30 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, it has been proposed that PD-L1-expressing tumor cells interact with PD-1-expressing T cells to attenuate T-cell activation and cancer cell evasion of immune surveillance, thereby resulting in impaired immune responses against tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
  • Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
  • Combination of a pd-1 antagonist and eribulin for treating urothelial cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0234] Research design

[0235] Described below is the use of moxibustion in combination with pembrolizumab in subjects with locally advanced or metastatic transitional cell urothelial carcinoma (mUC) previously treated with 0-2 chemotherapy regimens in the metastatic setting. An open-label, single-arm, multicenter, phase 1b / 2 study of Librelin. Figure 8 An example of the study design of a phase 1b / 2, open-label, single-arm, multicentre trial is shown. The number of subjects provided below for each phase of the study is a non-limiting example. Specific dosing regimens and / or amounts are also non-limiting. Those of ordinary skill in the art will appreciate that the number of subjects participating in a study can be increased or decreased. Those of ordinary skill in the art will understand how to modify dosage regimens and / or amounts for a particular patient or group of subjects.

[0236] Subjects / patients may be included in the study if they have locally advanced or meta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of urothelial cancer.

Description

[0001] References to related applications [0002] This application claims the benefit of US Provisional Application No. 62 / 408,328, filed October 14, 2016, the contents of which are hereby incorporated by reference in their entirety. [0003] sequence listing [0004] This application contains a Sequence Listing that has been filed electronically in ASCII form and is hereby incorporated by reference in its entirety. The ASCII copy, created on October 12, 2017, is named 213597_0003_00_WO_568866_SL and is 32,656 bytes in size. [0005] field of invention [0006] The present invention relates to combination therapies useful in the treatment of urothelial carcinoma (UC). Specifically, the present invention relates to a combination therapy comprising an antagonist of programmed death 1 protein (PD-1) and eribulin or a pharmaceutically acceptable salt thereof. [0007] Background of the invention [0008] PD-1 is thought to have a role in immune regulation as well as in the mai...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K31/357A61P35/00
CPCA61K39/39541A61K31/357A61K2039/545A61K45/06A61K47/183A61K9/0095A61K47/26A61P35/00A61P35/04A61P43/00A61K2300/00A61K39/39558A61K9/08A61K47/22C07K16/2818A61K2039/505A61K9/0019A61K31/351C07K16/2896C07K16/3038
Inventor M.S.奥利沃
Owner MERCK & CO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com